Emrah Can | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Dr. Emrah Can | Medicine and Health Sciences | Best Researcher Award

Prof. Dr. Emrah Can | Medicine and Health Sciences | Best Researcher Award | Professor| Istanbul University | Turkey

Prof. Dr. Emrah Can is a highly accomplished pediatrician and neonatology-focused clinician-scientist recognized for his extensive contributions to neonatal health, pediatric infectious diseases, neonatal sepsis, retinopathy of prematurity, and pediatric critical care. Prof. Dr. Emrah Can completed his medical training at Istanbul University Faculty of Medicine, followed by his medical specialization in Child Health and Diseases at Health Sciences University, İstanbul Bağcılar Training and Research Hospital, where he developed strong clinical expertise in neonatal nutrition, early sepsis biomarkers, high-risk neonatal monitoring, and pediatric intensive care. He progressed academically to the ranks of Associate Professor and Professor through consistent research productivity, clinical excellence, and mentorship. Throughout his career, Prof. Dr. Emrah Can has supervised numerous pediatric specialization theses focused on neonatal sepsis biomarkers, MRSA carriage among hospitalized children, melatonin levels in early sepsis, prognostic tools for pediatric traumatic brain injury, differentiation of lower respiratory tract infection and colonization in tracheostomized children, fetal malnutrition indicators, and hyperbilirubinemia-related risk factors, demonstrating his commitment to developing evidence-based pediatric protocols and training the next generation of pediatric specialists. His research interests include neonatal immunology, inflammation markers, nutritional interventions for premature infants, oxygen affinity biomarkers, neonatal thrombosis, and innovative hypothesis-driven models for predicting neonatal morbidity. His research skills include statistical analysis, advanced clinical data interpretation, hypothesis modeling, neonatal diagnostic model development, and interdisciplinary collaboration. Prof. Dr. Emrah Can has authored impactful publications in reputable journals such as Medical Hypotheses, International Ophthalmology, European Journal of Pediatrics, Pediatric Cardiology, and Journal of Paediatrics and Child Health, contributing significantly to early detection strategies for NEC, ROP, neonatal thrombosis, and hematologic alterations in neonates. His scientific memberships reflect his professional commitment, including active participation in the Pediatric Allergy and Asthma Academy Association, Turkish National Pediatric Association, Child Friends Association, and Turkish Neonatology Association. He has also served in academic administrative roles, including program head positions that highlight his leadership in medical education. Prof. Dr. Emrah Can has received recognition for his academic achievements, research contributions, and involvement in pediatric healthcare improvement initiatives. Overall, Prof. Dr. Emrah Can demonstrates exceptional clinical acumen, research innovation, collaborative engagement, and leadership in pediatric and neonatal medicine, positioning him as a scholar whose contributions continue to shape evidence-based neonatal care, advance scientific understanding of pediatric diseases, and improve health outcomes for vulnerable newborn populations.

Profile:  scopus | ORCID

Featured Publications

  1. Can, E. (2025). Development of a scoring model integrating inflammatory markers for predicting ROP in preterm neonates. International Ophthalmology.

  2. Can, E. (2025). Postnatal hemoglobin P50 as a surrogate marker for hypoxia-driven NEC in preterm infants: A mechanistic hypothesis. Medical Hypotheses.

  3. Can, E. (2025). Phototherapy modifies hematologic markers without inducing inflammation in neonates: A retrospective observational study. European Journal of Pediatrics.

  4. Can, E. (2025). Could parabiotics safely enhance immune maturation and mitigate NEC/sepsis in preterm neonates? Medical Hypotheses.

  5. Can, E. (2025). Early haemoglobin oxygen affinity as a hypothesis-generating marker for retinopathy of prematurity risk in preterm infants. Journal of Paediatrics and Child Health.

  6. Can, E. (2025). Neonatal portal vein thrombosis: A case series from a tertiary NICU. Pediatric Cardiology.

 

Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award | Pharmaceutical | Abdul Wali Khan University Mardan | Pakistan

Dr. Muhammad Bilal Afridi is a dedicated pharmaceutical scientist and clinical pharmacist recognized for his expertise in drug synthesis, pharmacological modeling, and computational chemistry. With a profound academic background and more than a decade of professional experience, Dr. Afridi has established himself as a leading researcher in the domain of synthetic and therapeutic drug development. He earned his Ph.D. in Pharmaceutical Sciences from Abdul Wali Khan University, Mardan, where his doctoral research focused on the synthesis, characterization, computational studies, and pharmacological potential of synthetic curcumin derivatives aimed at addressing diabetes and amnesia-related disorders. His earlier academic milestones include an M.Phil in Pharmaceutical Sciences from Abdul Wali Khan University and a Doctor of Pharmacy (Pharm-D) from Kohat University of Science and Technology. Professionally, Dr. Muhammad Bilal Afridi has served as a pharmacist at the Institute of Kidney Diseases (IKD), Peshawar, where he managed hospital pharmacy operations, clinical pharmacy services, and patient safety programs. His leadership extended to training junior pharmacists, supervising pharmacy interns, and participating in institutional Drug and Therapeutic Committees. His previous tenures at Rehman Medical Institute and D. Watson Chemist allowed him to develop robust skills in patient counseling, prescription review, pharmacovigilance, and rational drug use. Dr. Afridi’s research interests encompass computational drug design, molecular docking, pharmacodynamics, and synthesis of bioactive compounds, reflecting his interdisciplinary approach that bridges chemistry, pharmacology, and computational biology. His published works in highly regarded journals, including Computational Biology and Chemistry, Inorganic Chemistry Communications, and Current Molecular Pharmacology, contribute significantly to advancing medicinal chemistry and pharmaceutical innovation. He has demonstrated strong analytical and technical skills in density functional theory (DFT) modeling, ADMET prediction, and spectral analysis. Dr. Muhammad Bilal Afridi’s professional competencies include teaching, mentoring, research supervision, and scientific writing, backed by proficiency in tools like EndNote and MS Office. His contributions have been acknowledged through multiple peer-reviewed publications, collaborations with international researchers from Türkiye and Saudi Arabia, and recognition in academic circles for his commitment to scientific excellence. He continues to serve as a role model for young researchers in Pakistan through his dedication to patient-centered research and academic mentorship. His unwavering commitment to bridging pharmaceutical sciences and clinical applications makes him a strong candidate for recognition in global research excellence. Dr. Muhammad Bilal Afridi stands as an emerging leader with a promising future in international pharmaceutical research, committed to innovation, integrity, and impactful contributions to human health and medicine.

Profile: Scopus

Featured Publications 

  1. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). SwissADME studies and density functional theory (DFT) approaches of methyl substituted curcumin derivatives. Computational Biology and Chemistry, 112, 108153. (Cited by 8)

  2. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives. Inorganic Chemistry Communications, 168, 112943. (Cited by 6)

  3. Afridi, M. B., Khan, H., Ali Shah, S. W., Zafar, M., Almalki, A. S., Ghias, M., & Rahman, N. (2022). In-vivo anti-nociceptive activities of Schiff bases aldehyde derivatives of 4-aminoantipyrine and their molecular docking studies. Main Group Chemistry, 21(2), 373–386. (Cited by 10)

  4. Afridi, M. B., Khan, H., Akkol, E. K., & Aschner, M. (2021). Pain perception and management: Where do we stand? Current Molecular Pharmacology, 14(5), 678–688. (Cited by 25)

  5. Afridi, M. B., Sardar, H., Shah, S. W. A., Serdaroğlu, G., & Khan, H. (2025). Exploring anticholinergic and anti-amnesic potential of methyl substituted monocarbonyl curcumin derivatives. European Journal of Pharmacology, 950, 182653. (Cited by 2)

  6. Afridi, M. B., Khan, H., & Shah, S. W. A. (2023). Computational evaluation of synthetic curcumin analogs for neuroprotective potential using molecular docking approaches. Journal of Molecular Structure, 1287, 135623. (Cited by 4)

  7. Afridi, M. B., Sardar, H., & Khan, H. (2023). Pharmacological insights into curcumin derivatives: A computational and experimental perspective. Bioorganic Chemistry, 137, 106707. (Cited by 3)